IL1B and inflammatory bowel disease: Furthermore, treatment of inflammatory bowel disease (IBD)-induced mice with compound 1 decreased myeloperoxidase activity in colonic extracts and modulated the colon length and serum levels of cytokines such as TNF–α, IFN–γ, IL–6, IL–1β, and IL–10 [31,32].